Published in Br J Cancer on April 10, 2007
Bax expression is a candidate prognostic and predictive marker of colorectal cancer. J Gastrointest Oncol (2010) 1.24
Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents. J Clin Oncol (2008) 1.13
Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw (2011) 0.95
The prognostic value of the apoptosis pathway in colorectal cancer: a review of the literature on biomarkers identified by immunohistochemistry. Biomark Cancer (2013) 0.94
Tumor suppressors miR-143 and miR-145 and predicted target proteins API5, ERK5, K-RAS, and IRS-1 are differentially expressed in proximal and distal colon. Am J Physiol Gastrointest Liver Physiol (2014) 0.92
Somatic gene copy number alterations in colorectal cancer: new quest for cancer drivers and biomarkers. Oncogene (2015) 0.89
Impact of chromosomal instability on colorectal cancer progression and outcome. BMC Cancer (2014) 0.87
TGFBR2 and BAX mononucleotide tract mutations, microsatellite instability, and prognosis in 1072 colorectal cancers. PLoS One (2011) 0.86
Is Bax/Bcl-2 ratio considered as a prognostic marker with age and tumor location in colorectal cancer? Iran Biomed J (2015) 0.85
Review of the molecular profile and modern prognostic markers for gastric lymphoma: how do they affect clinical practice? Can J Surg (2012) 0.82
Prognostic implications of BAX protein expression and microsatellite instability in all non-metastatic stages of primary colon cancer treated by surgery alone. Int J Colorectal Dis (2009) 0.82
Abnormal expression of GADD45B in human colorectal carcinoma. J Transl Med (2012) 0.81
Lack of association between Bax promoter (-248G>A) single nucleotide polymorphism and susceptibility towards cancer: evidence from a meta-analysis. PLoS One (2013) 0.79
Predictive or non-predictive, prognostic or non-prognostic: Dilemmas generated through small retrospective studies. J Gastrointest Oncol (2010) 0.75
BG-4, a novel anticancer peptide from bitter gourd (Momordica charantia), promotes apoptosis in human colon cancer cells. Sci Rep (2016) 0.75
BaxΔ2 Family Alternative Splicing Salvages Bax Microsatellite-Frameshift Mutations. Genes Cancer (2013) 0.75
A genetic model for colorectal tumorigenesis. Cell (1990) 44.37
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 35.74
Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell (1993) 20.72
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell (1995) 14.90
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med (2003) 12.17
Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol (2005) 8.15
Double identity for proteins of the Bcl-2 family. Nature (1997) 5.60
Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med (2001) 5.22
Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood (1996) 5.13
Role of BAX in the apoptotic response to anticancer agents. Science (2000) 5.07
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) J Clin Oncol (1999) 4.79
Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. Proc Natl Acad Sci U S A (1995) 4.22
Molecular regulation of apoptosis: genetic controls on cell death. Cell (1993) 3.57
Bcl-2 family proteins. Oncogene (1998) 3.56
Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology (1999) 3.06
BCL-2 gene family and the regulation of programmed cell death. Cancer Res (1999) 2.89
BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res (1997) 2.77
Bcl-2 and Bax function independently to regulate cell death. Nat Genet (1997) 2.64
Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res (1998) 2.21
Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res (2001) 2.12
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer (1998) 2.09
Cancer of the microsatellite mutator phenotype. Biol Chem (1996) 1.91
Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene (1994) 1.88
P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res (2001) 1.74
The mismatch repair complex hMutS alpha recognizes 5-fluorouracil-modified DNA: implications for chemosensitivity and resistance. Gastroenterology (2004) 1.62
A new TNM staging strategy for node-positive (stage III) colon cancer: an analysis of 50,042 patients. Ann Surg (2002) 1.48
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol (2004) 1.41
Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases. J Clin Oncol (1999) 1.40
Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin Cancer Res (1995) 1.21
Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L). Cancer Res (2002) 1.20
5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol (2003) 1.17
Critical requirement of BAX for manifestation of apoptosis induced by multiple stimuli in human epithelial cancer cells. Cancer Res (2002) 1.16
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis (2003) 1.07
Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol (2001) 1.05
Induction of the death-promoting gene bax-alpha sensitizes cultured breast-cancer cells to drug-induced apoptosis. Int J Cancer (1996) 0.93
Adjuvant therapy of colon cancer. Semin Oncol (2001) 0.92
Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors. Int J Cancer (2002) 0.91
Molecular staging of colorectal cancer in African-American and Caucasian patients using phenotypic expression of p53, Bcl-2, MUC-1 AND p27(kip-1). Int J Cancer (2002) 0.89
Low BAX protein expression correlates with disease recurrence in preoperatively irradiated rectal carcinoma. Int J Radiat Oncol Biol Phys (2005) 0.85
Immunohistochemical detection of p53 and Bcl-2 in colorectal carcinoma: no evidence for prognostic significance. Br J Cancer (1998) 0.82
The Vienna classification of gastrointestinal epithelial neoplasia. Gut (2000) 9.39
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol (2011) 4.95
Non-alcoholic duct destructive chronic pancreatitis. Gut (1997) 2.79
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res (1999) 2.51
Attempted endoscopic en bloc resection of mucosal and submucosal tumors using insulated-tip knives: a pilot series. Endoscopy (2004) 2.07
[S3-Guidelines Conference "Colorectal Carcinoma" 2004]. Z Gastroenterol (2004) 2.03
Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1994) 1.96
Slug is overexpressed in gastric carcinomas and may act synergistically with SIP1 and Snail in the down-regulation of E-cadherin. J Pathol (2007) 1.91
Gastritis due to spiral shaped bacteria other than Helicobacter pylori: clinical, histological, and ultrastructural findings. Gut (1991) 1.83
Pyloric gland adenoma: a clinico-pathological analysis of 90 cases. Virchows Arch (2003) 1.82
[Update S3-guideline "colorectal cancer" 2008]. Z Gastroenterol (2008) 1.81
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. Gut (2003) 1.66
Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. Eur J Cancer (2009) 1.62
Hepatic retinopathia. Changes in retinal function. Vision Res (1997) 1.58
Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer (2008) 1.57
Isolation and partial characterization of a fatty acid binding protein in rat liver plasma membranes. Proc Natl Acad Sci U S A (1985) 1.55
A functional CFTR protein is required for mouse intestinal cAMP-, cGMP- and Ca(2+)-dependent HCO3- secretion. J Physiol (1997) 1.55
Guanylin strongly stimulates rat duodenal HCO3- secretion: proposed mechanism and comparison with other secretagogues. Gastroenterology (1996) 1.53
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52
Analysis of the E-cadherin repressor Snail in primary human cancers. Cells Tissues Organs (2007) 1.52
[S3-guideline colorectal cancer version 1.0]. Z Gastroenterol (2013) 1.51
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Ann Oncol (2012) 1.49
Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res (1998) 1.47
High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. Bone Marrow Transplant (2002) 1.46
Premature trypsinogen activation during cerulein pancreatitis in rats occurs inside pancreatic acinar cells. Pancreas (1998) 1.45
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Prognostic influence of p53 expression in gastric cancer. J Pathol (1996) 1.43
Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon gamma. Gut (2002) 1.41
[Acute mitral insufficiency in osteogenesis imperfecta]. Dtsch Med Wochenschr (1994) 1.41
Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagus. Gastroenterology (1998) 1.41
[Order in the chaos of classifications of erosions of the gastric mucosa]. Leber Magen Darm (1993) 1.39
Evaluation of endosonography in sclerotherapy of esophageal varices. Endoscopy (1991) 1.39
[Acute gastrointestinal side effects of radiotherapy. What is certain in the treatment?]. Strahlenther Onkol (1996) 1.38
Pattern of gastric endocrine cells in microcarcinoidosis--an immunohistochemical study of 14 gastric biopsies. Virchows Arch (1996) 1.37
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer (2008) 1.35
Overexpression or ectopic expression of MUC2 is the common property of mucinous carcinomas of the colon, pancreas, breast, and ovary. J Pathol (1997) 1.34
Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer (2001) 1.29
Caspase-8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene (2000) 1.27
Sendai virus infection induces apoptosis through activation of caspase-8 (FLICE) and caspase-3 (CPP32). J Virol (1999) 1.27
Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes Cancer (1998) 1.23
Keratinocyte growth factor is highly overexpressed in inflammatory bowel disease. Am J Pathol (1996) 1.21
Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer (1998) 1.21
Family occurrence of achalasia and diffuse spasm of the oesophagus. Gut (1988) 1.21
S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII). Z Gastroenterol (2010) 1.20
Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol (2010) 1.20
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol (2001) 1.20
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer (2000) 1.19
Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study. J Clin Pathol (2006) 1.18
5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. Ann Oncol (2003) 1.17
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol (1999) 1.16
Epidemiology of Whipple's disease in Germany. Analysis of 110 patients diagnosed in 1965-95. Scand J Gastroenterol (1997) 1.16
cAMP-mediated regulation of murine intestinal/pancreatic Na+/HCO3- cotransporter subtype pNBC1. Am J Physiol Gastrointest Liver Physiol (2002) 1.13
The Na+/H+ exchanger isoform 2 is the predominant NHE isoform in murine colonic crypts and its lack causes NHE3 upregulation. Am J Physiol Gastrointest Liver Physiol (2004) 1.12
Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol (1998) 1.11
Histopathological diagnosis of Barrett's mucosa and associated neoplasias: results of a consensus conference of the Working Group for Gastroenterological Pathology of the German Society for Pathology on 22 September 2001 in Erlangen. Virchows Arch (2003) 1.11
Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis (2008) 1.10
High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology (2006) 1.10
Vascularization of carcinomas of the esophagus and its correlation with tumor proliferation. Cancer Res (1994) 1.09
Esophageal cancer. Autopsy findings in 171 cases. Arch Pathol Lab Med (1984) 1.08
Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol (2014) 1.07
Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature. Int J Colorectal Dis (2003) 1.07
Role of Na(+)HCO(3)(-) cotransporter NBC1, Na(+)/H(+) exchanger NHE1, and carbonic anhydrase in rabbit duodenal bicarbonate secretion. Gastroenterology (2000) 1.07
Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki-67 immunostaining. Int J Cancer (1991) 1.07
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol (2014) 1.07
Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol (2004) 1.06
Bismuth absorption from the stomach and small intestine. Gastroenterology (1992) 1.06
An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer (2011) 1.06
Gut hormones in tropical malabsorption. Br Med J (1979) 1.05
Treatment of brain metastases in patients with testicular cancer. J Clin Oncol (1997) 1.04
Effects of antioxidants and free radical scavengers in three different models of acute pancreatitis. Pancreas (1992) 1.03
Carcinoma of the gallbladder: autopsy findings in 287 cases and review of the literature. J Surg Oncol (1985) 1.03
Collagenous gastroduodenitis on collagenous colitis. Endoscopy (1990) 1.02
Detection of elevated caspase activation and early apoptosis in liver diseases. Eur J Cell Biol (2001) 1.02
Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol (2001) 1.02
'Pyloric gland-type adenoma' arising in heterotopic gastric mucosa of the duodenum, with dysplastic progression of the gastric type. Virchows Arch (1999) 1.02
First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial. Br J Cancer (2003) 1.01
p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer (1994) 1.01